Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab

Documenti analoghi

• Successful treatment of checkpoint inhibitor‐associated bullous pemphigoid with dupilumab in a patient with angiosarcoma
  di: Inga Hansen, et al.
  Pubblicazione: (2024)
• Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor abrocitinib
  di: Alexander Michels, et al.
  Pubblicazione: (2024)
• Severe mixed hand and generalized eczema treated with the JAK inhibitor upadacitinib
  di: Neda Cramer, et al.
  Pubblicazione: (2024)
• Two cases of dupilumab‐induced vitiligo
  di: Ana Ferreirinha, et al.
  Pubblicazione: (2024)
• Kimura disease: Successful treatment with dupilumab
  di: Jing Zeng, et al.
  Pubblicazione: (2025)